A study at Baylor College of Medicine, published in the journal Essential communication.
The research team found that a An enzyme called MAPK4 is important in cancer growth and plays an important role in triple negative breast cancer. (TNBC?? a dangerous form of breast cancer) and resistance to some therapies.
‘A new therapeutic target for patients with triple negative breast cancer (TNBC?? a dangerous form of breast cancer) has been discovered. An enzyme called MAPK4 was found to play an important role in TNBC. ‘
It is seen that 70 to 80% TNBC (30% or more in the basal-like breast cancer subtype) presenting significant levels of MAPK4.
Furthermore, knockdown of MAPK4 reduces human TNBC cell proliferation in animal models and sensitizes cells to therapies (especially those that block the PI3K ??signaling pathway) promote cancer growth).
“Overall, our findings suggest a new therapeutic opportunity for TNBC based on MAPK4 expression, perhaps including a combination of inhibitors to help control cancer growth. Future research will help clarify this idea.” said the corresponding author, Dr. Feng Yang, assistant professor of molecular and cellular biology and a member of the Dan L Duncan Comprehensive Cancer Center at Baylor.